Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
WALTHAM, Mass., May 14, 2021 (GLOBE NEWSWIRE) -- Eloxx Pharmaceuticals, Inc. (the “Company”) (Nasdaq: ELOX), a leader in ribosomal RNA-targeted genetic therapies for rare diseases, today announced...
-
WALTHAM, Mass., May 13, 2021 (GLOBE NEWSWIRE) -- Eloxx Pharmaceuticals, Inc. (the “Company”) (Nasdaq: ELOX), a leader in ribosomal RNA-targeted genetic therapies for rare diseases, today announced...
-
Acquisition of Zikani Therapeutics, Ribosomal Modulation Company; Combined Company Advancing Ribosomal RNA-Targeted Genetic Therapies Additional Treatment Arm Added to Ongoing Phase 2 Clinical...
-
Fifth Treatment Arm to Evaluate Safety of ELX-02 in Combination with Kalydeco (ivacaftor) Reaffirmed Data Readout for First Four Treatment Arms On Track for Second Half of 2021 WALTHAM, Mass., April...
-
Combined Company to be Leader in Ribosomal RNA-Targeted Genetic Therapy Bringing Together Complementary Platforms Maximizes Potential for ELX-02 for Cystic Fibrosis in Phase 2 Development Adds...
-
We expect to report top line data from our Phase 2 cystic fibrosis clinical trials in the first half of this year We have expanded our global Phase 2 clinical trial beyond the U.S., Europe and...
-
WALTHAM, Mass., March 04, 2021 (GLOBE NEWSWIRE) -- Eloxx Pharmaceuticals, Inc. (NASDAQ: ELOX), a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel...
-
WALTHAM, Mass., Feb. 09, 2021 (GLOBE NEWSWIRE) -- Eloxx Pharmaceuticals, Inc., (NASDAQ: ELOX) a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel...
-
Publication titled: “A Randomized, Double-Blind, Placebo-Controlled, Multiple Dose Escalation Study to Evaluate the Safety and Pharmacokinetics of ELX-02 in Healthy Subjects” WALTHAM, Mass., Jan. ...
-
WALTHAM, Mass., Jan. 20, 2021 (GLOBE NEWSWIRE) -- Eloxx Pharmaceuticals, Inc., (NASDAQ: ELOX) a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel...